NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial compares the safety and effectiveness of catheter ablation for PAF with antiarrhythmic drug therapy. The investigational catheter being studied is the NAVISTAR® THERMOCOOL® irrigated-tip catheter. At the time of this study, the NAVISTAR® THERMOCOOL® catheter was FDA-approved for commercial distribution in the U.S. for treating patients with Type I atrial flutter and drug refractory monomorphic ventricular tachycardia post myocardial infarction. The catheter was approved for use in Europe for endocardial ablation for treating cardiac arrhythmias.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biosense Webster, Inc.
• Treatments: Anti-Arrhythmia Agents

Criteria

You may be eligible to participate in this study if you: Have failed to respond to drug treatment for your AFib, or find the side effects of your medication intolerable.

Inclusion Criteria

• Patients with symptomatic PAF who have had three (3) AF episodes in the six (6) months prior to randomization, one of which must be documented. Documentation may include electrocardiogram (ECG), transtelephonic monitor (TTM), Holter monitor (HM), or telemetry strip.

• Failure of at least one AAD for PAF [class I or III or AV nodal blocking agents such as beta blockers (BB) and calcium channel blockers (CCB)] as evidenced by recurrent symptomatic PAF, or intolerable side effects due to AAD.

• Signed Patient Informed Consent Form.

• Age 18 years or older.

• Able and willing to comply with all pre-, post- and follow-up testing and requirements.

Exclusion Criteria

• Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.

• Previous ablation for atrial fibrillation.

• Patients on amiodarone therapy at any time during the previous six (6) months.

• AF episodes that last longer than 30 days and are terminated via cardioversion.

• Any valvular cardiac surgical procedure.

• CABG procedure within the last 180 days (six months).

• Awaiting cardiac transplantation or other cardiac surgery within the next 360 days (12 months).

• Documented left atrial thrombus on imaging (e.g. TEE).

• History of a documented thromboembolic event within the past one (1) year.

• Diagnosed atrial myxoma.

• Presence of implanted ICD.

• Significant pulmonary disease, (e.g. restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms.

• Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.

• Women who are pregnant (by history of menstrual period or pregnancy test if the history is considered unreliable).

• Acute illness or active systemic infection or sepsis.

• Unstable angina.

• Myocardial infarction within the previous 60 days (two months).

• LVEF < 40%.

• History of blood clotting or bleeding abnormalities.

• Contraindication to anticoagulation (i.e. heparin or warfarin).

• Contraindication to CT/MRA procedure.

• Life expectancy less than 360 days (12 months).

• Enrollment in an investigational study evaluating another device or drug.

• Uncontrolled heart failure or NYHA class III or IV heart failure.

• Presence of intramural thrombus, tumor or other abnormality that precludes catheter introduction or manipulation.

• Presence of a condition that precludes vascular access.

• Left atrial size ≥ 50 mm